ContractExclusive License Agreement • August 9th, 2023 • Precigen, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 9th, 2023 Company Industry Jurisdiction
Certain identified information marked with [***] has been excluded from this exhibit because it is not material and is of the type that the registrant treats as private and confidential. AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 10th, 2023 • Alaunos Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 10th, 2023 Company Industry JurisdictionThis AMENDED AND RESTATED Exclusive License Agreement (the “Agreement”) is entered into as of April 3, 2023 (the “Effective Date”) replaces in its entirety the Exclusive License Agreement entered into on October 5, 2018 (the “ELA Agreement”) by and between Alaunos Therapeutics (formerly known as ZIOPHARM Oncology, Inc.), a Delaware corporation, with its principal place of business at 8030 El Rio, Houston TX 77054 (“Alaunos”), and Precigen, Inc., a Virginia corporation, with its principal place of business at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Precigen”). Alaunos and Precigen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
ContractExclusive License Agreement • May 10th, 2023 • Precigen, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 10th, 2023 Company Industry Jurisdiction